Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Checkpoint Inhibitor Refractory Cancer Market Size Growth Rate by Type, 2018 VS 2022 VS 2033
1.2.2 PD-1 Inhibitors
1.2.3 PD-L1 Inhibitors
1.3 Market by Application
1.3.1 Global Checkpoint Inhibitor Refractory Cancer Market Size Growth Rate by Application, 2018 VS 2022 VS 2033
1.3.2 Hodgkin Lymphoma
1.3.3 Kidney Cancer
1.3.4 Melanoma
1.3.5 Non-Small Cell Lung Cancer
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Checkpoint Inhibitor Refractory Cancer Market Perspective (2018-2033)
2.2 Global Checkpoint Inhibitor Refractory Cancer Growth Trends by Region
2.2.1 Checkpoint Inhibitor Refractory Cancer Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Checkpoint Inhibitor Refractory Cancer Historic Market Size by Region (2018-2023)
2.2.3 Checkpoint Inhibitor Refractory Cancer Forecasted Market Size by Region (2024-2033)
2.3 Checkpoint Inhibitor Refractory Cancer Market Dynamics
2.3.1 Checkpoint Inhibitor Refractory Cancer Industry Trends
2.3.2 Checkpoint Inhibitor Refractory Cancer Market Drivers
2.3.3 Checkpoint Inhibitor Refractory Cancer Market Challenges
2.3.4 Checkpoint Inhibitor Refractory Cancer Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Checkpoint Inhibitor Refractory Cancer by Players
3.1.1 Global Checkpoint Inhibitor Refractory Cancer Revenue by Players (2018-2023)
3.1.2 Global Checkpoint Inhibitor Refractory Cancer Revenue Market Share by Players (2018-2023)
3.2 Global Checkpoint Inhibitor Refractory Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Checkpoint Inhibitor Refractory Cancer, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Checkpoint Inhibitor Refractory Cancer Market Concentration Ratio
3.4.1 Global Checkpoint Inhibitor Refractory Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Checkpoint Inhibitor Refractory Cancer Revenue in 2022
3.5 Global Key Players of Checkpoint Inhibitor Refractory Cancer Head office and Area Served
3.6 Global Key Players of Checkpoint Inhibitor Refractory Cancer, Product and Application
3.7 Global Key Players of Checkpoint Inhibitor Refractory Cancer, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Checkpoint Inhibitor Refractory Cancer Breakdown Data by Type
4.1 Global Checkpoint Inhibitor Refractory Cancer Historic Market Size by Type (2018-2023)
4.2 Global Checkpoint Inhibitor Refractory Cancer Forecasted Market Size by Type (2024-2033)
5 Checkpoint Inhibitor Refractory Cancer Breakdown Data by Application
5.1 Global Checkpoint Inhibitor Refractory Cancer Historic Market Size by Application (2018-2023)
5.2 Global Checkpoint Inhibitor Refractory Cancer Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Checkpoint Inhibitor Refractory Cancer Market Size (2018-2033)
6.2 North America Checkpoint Inhibitor Refractory Cancer Market Size by Type
6.2.1 North America Checkpoint Inhibitor Refractory Cancer Market Size by Type (2018-2023)
6.2.2 North America Checkpoint Inhibitor Refractory Cancer Market Size by Type (2024-2033)
6.2.3 North America Checkpoint Inhibitor Refractory Cancer Market Share by Type (2018-2033)
6.3 North America Checkpoint Inhibitor Refractory Cancer Market Size by Application
6.3.1 North America Checkpoint Inhibitor Refractory Cancer Market Size by Application (2018-2023)
6.3.2 North America Checkpoint Inhibitor Refractory Cancer Market Size by Application (2024-2033)
6.3.3 North America Checkpoint Inhibitor Refractory Cancer Market Share by Application (2018-2033)
6.4 North America Checkpoint Inhibitor Refractory Cancer Market Size by Country
6.4.1 North America Checkpoint Inhibitor Refractory Cancer Market Size by Country: 2018 VS 2022 VS 2033
6.4.2 North America Checkpoint Inhibitor Refractory Cancer Market Size by Country (2018-2023)
6.4.3 North America Checkpoint Inhibitor Refractory Cancer Market Size by Country (2024-2033)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Checkpoint Inhibitor Refractory Cancer Market Size (2018-2033)
7.2 Europe Checkpoint Inhibitor Refractory Cancer Market Size by Type
7.2.1 Europe Checkpoint Inhibitor Refractory Cancer Market Size by Type (2018-2023)
7.2.2 Europe Checkpoint Inhibitor Refractory Cancer Market Size by Type (2024-2033)
7.2.3 Europe Checkpoint Inhibitor Refractory Cancer Market Share by Type (2018-2033)
7.3 Europe Checkpoint Inhibitor Refractory Cancer Market Size by Application
7.3.1 Europe Checkpoint Inhibitor Refractory Cancer Market Size by Application (2018-2023)
7.3.2 Europe Checkpoint Inhibitor Refractory Cancer Market Size by Application (2024-2033)
7.3.3 Europe Checkpoint Inhibitor Refractory Cancer Market Share by Application (2018-2033)
7.4 Europe Checkpoint Inhibitor Refractory Cancer Market Size by Country
7.4.1 Europe Checkpoint Inhibitor Refractory Cancer Market Size by Country: 2018 VS 2022 VS 2033
7.4.2 Europe Checkpoint Inhibitor Refractory Cancer Market Size by Country (2018-2023)
7.4.3 Europe Checkpoint Inhibitor Refractory Cancer Market Size by Country (2024-2033)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Checkpoint Inhibitor Refractory Cancer Market Size (2018-2033)
8.2 China Checkpoint Inhibitor Refractory Cancer Market Size by Type
8.2.1 China Checkpoint Inhibitor Refractory Cancer Market Size by Type (2018-2023)
8.2.2 China Checkpoint Inhibitor Refractory Cancer Market Size by Type (2024-2033)
8.2.3 China Checkpoint Inhibitor Refractory Cancer Market Share by Type (2018-2033)
8.3 China Checkpoint Inhibitor Refractory Cancer Market Size by Application
8.3.1 China Checkpoint Inhibitor Refractory Cancer Market Size by Application (2018-2023)
8.3.2 China Checkpoint Inhibitor Refractory Cancer Market Size by Application (2024-2033)
8.3.3 China Checkpoint Inhibitor Refractory Cancer Market Share by Application (2018-2033)
9 Asia (excluding China)
9.1 Asia Checkpoint Inhibitor Refractory Cancer Market Size (2018-2033)
9.2 Asia Checkpoint Inhibitor Refractory Cancer Market Size by Type
9.2.1 Asia Checkpoint Inhibitor Refractory Cancer Market Size by Type (2018-2023)
9.2.2 Asia Checkpoint Inhibitor Refractory Cancer Market Size by Type (2024-2033)
9.2.3 Asia Checkpoint Inhibitor Refractory Cancer Market Share by Type (2018-2033)
9.3 Asia Checkpoint Inhibitor Refractory Cancer Market Size by Application
9.3.1 Asia Checkpoint Inhibitor Refractory Cancer Market Size by Application (2018-2023)
9.3.2 Asia Checkpoint Inhibitor Refractory Cancer Market Size by Application (2024-2033)
9.3.3 Asia Checkpoint Inhibitor Refractory Cancer Market Share by Application (2018-2033)
9.4 Asia Checkpoint Inhibitor Refractory Cancer Market Size by Region
9.4.1 Asia Checkpoint Inhibitor Refractory Cancer Market Size by Region: 2018 VS 2022 VS 2033
9.4.2 Asia Checkpoint Inhibitor Refractory Cancer Market Size by Region (2018-2023)
9.4.3 Asia Checkpoint Inhibitor Refractory Cancer Market Size by Region (2024-2033)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Checkpoint Inhibitor Refractory Cancer Market Size (2018-2033)
10.2 Middle East, Africa, and Latin America Checkpoint Inhibitor Refractory Cancer Market Size by Type
10.2.1 Middle East, Africa, and Latin America Checkpoint Inhibitor Refractory Cancer Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Checkpoint Inhibitor Refractory Cancer Market Size by Type (2024-2033)
10.2.3 Middle East, Africa, and Latin America Checkpoint Inhibitor Refractory Cancer Market Share by Type (2018-2033)
10.3 Middle East, Africa, and Latin America Checkpoint Inhibitor Refractory Cancer Market Size by Application
10.3.1 Middle East, Africa, and Latin America Checkpoint Inhibitor Refractory Cancer Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Checkpoint Inhibitor Refractory Cancer Market Size by Application (2024-2033)
10.3.3 Middle East, Africa, and Latin America Checkpoint Inhibitor Refractory Cancer Market Share by Application (2018-2033)
10.4 Middle East, Africa, and Latin America Checkpoint Inhibitor Refractory Cancer Market Size by Country
10.4.1 Middle East, Africa, and Latin America Checkpoint Inhibitor Refractory Cancer Market Size by Country: 2018 VS 2022 VS 2033
10.4.2 Middle East, Africa, and Latin America Checkpoint Inhibitor Refractory Cancer Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Checkpoint Inhibitor Refractory Cancer Market Size by Country (2024-2033)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Details
11.1.2 Bristol-Myers Squibb Business Overview
11.1.3 Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Introduction
11.1.4 Bristol-Myers Squibb Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.1.5 Bristol-Myers Squibb Recent Developments
11.2 AstraZeneca
11.2.1 AstraZeneca Company Details
11.2.2 AstraZeneca Business Overview
11.2.3 AstraZeneca Checkpoint Inhibitor Refractory Cancer Introduction
11.2.4 AstraZeneca Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.2.5 AstraZeneca Recent Developments
11.3 Merck
11.3.1 Merck Company Details
11.3.2 Merck Business Overview
11.3.3 Merck Checkpoint Inhibitor Refractory Cancer Introduction
11.3.4 Merck Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.3.5 Merck Recent Developments
11.4 Roche
11.4.1 Roche Company Details
11.4.2 Roche Business Overview
11.4.3 Roche Checkpoint Inhibitor Refractory Cancer Introduction
11.4.4 Roche Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.4.5 Roche Recent Developments
11.5 Regeneron Pharmaceuticals
11.5.1 Regeneron Pharmaceuticals Company Details
11.5.2 Regeneron Pharmaceuticals Business Overview
11.5.3 Regeneron Pharmaceuticals Checkpoint Inhibitor Refractory Cancer Introduction
11.5.4 Regeneron Pharmaceuticals Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.5.5 Regeneron Pharmaceuticals Recent Developments
11.6 Bristol-Myers Squibb
11.6.1 Bristol-Myers Squibb Company Details
11.6.2 Bristol-Myers Squibb Business Overview
11.6.3 Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Introduction
11.6.4 Bristol-Myers Squibb Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.6.5 Bristol-Myers Squibb Recent Developments
11.7 Janssen Research and Development
11.7.1 Janssen Research and Development Company Details
11.7.2 Janssen Research and Development Business Overview
11.7.3 Janssen Research and Development Checkpoint Inhibitor Refractory Cancer Introduction
11.7.4 Janssen Research and Development Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.7.5 Janssen Research and Development Recent Developments
11.8 4D pharma
11.8.1 4D pharma Company Details
11.8.2 4D pharma Business Overview
11.8.3 4D pharma Checkpoint Inhibitor Refractory Cancer Introduction
11.8.4 4D pharma Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.8.5 4D pharma Recent Developments
11.9 4SC AG
11.9.1 4SC AG Company Details
11.9.2 4SC AG Business Overview
11.9.3 4SC AG Checkpoint Inhibitor Refractory Cancer Introduction
11.9.4 4SC AG Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.9.5 4SC AG Recent Developments
11.10 OncoSec Medical
11.10.1 OncoSec Medical Company Details
11.10.2 OncoSec Medical Business Overview
11.10.3 OncoSec Medical Checkpoint Inhibitor Refractory Cancer Introduction
11.10.4 OncoSec Medical Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.10.5 OncoSec Medical Recent Developments
11.11 Mirati Therapeutics
11.11.1 Mirati Therapeutics Company Details
11.11.2 Mirati Therapeutics Business Overview
11.11.3 Mirati Therapeutics Checkpoint Inhibitor Refractory Cancer Introduction
11.11.4 Mirati Therapeutics Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.11.5 Mirati Therapeutics Recent Developments
11.12 Ascentage Pharma Group
11.12.1 Ascentage Pharma Group Company Details
11.12.2 Ascentage Pharma Group Business Overview
11.12.3 Ascentage Pharma Group Checkpoint Inhibitor Refractory Cancer Introduction
11.12.4 Ascentage Pharma Group Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.12.5 Ascentage Pharma Group Recent Developments
11.13 ENB Therapeutics
11.13.1 ENB Therapeutics Company Details
11.13.2 ENB Therapeutics Business Overview
11.13.3 ENB Therapeutics Checkpoint Inhibitor Refractory Cancer Introduction
11.13.4 ENB Therapeutics Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.13.5 ENB Therapeutics Recent Developments
11.14 Exicure
11.14.1 Exicure Company Details
11.14.2 Exicure Business Overview
11.14.3 Exicure Checkpoint Inhibitor Refractory Cancer Introduction
11.14.4 Exicure Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.14.5 Exicure Recent Developments
11.15 Eisai
11.15.1 Eisai Company Details
11.15.2 Eisai Business Overview
11.15.3 Eisai Checkpoint Inhibitor Refractory Cancer Introduction
11.15.4 Eisai Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.15.5 Eisai Recent Developments
11.16 Kartos Therapeutics
11.16.1 Kartos Therapeutics Company Details
11.16.2 Kartos Therapeutics Business Overview
11.16.3 Kartos Therapeutics Checkpoint Inhibitor Refractory Cancer Introduction
11.16.4 Kartos Therapeutics Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.16.5 Kartos Therapeutics Recent Developments
11.17 Exelixis
11.17.1 Exelixis Company Details
11.17.2 Exelixis Business Overview
11.17.3 Exelixis Checkpoint Inhibitor Refractory Cancer Introduction
11.17.4 Exelixis Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.17.5 Exelixis Recent Developments
11.18 ImmunityBio
11.18.1 ImmunityBio Company Details
11.18.2 ImmunityBio Business Overview
11.18.3 ImmunityBio Checkpoint Inhibitor Refractory Cancer Introduction
11.18.4 ImmunityBio Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
11.18.5 ImmunityBio Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Checkpoint Inhibitor Refractory Cancer Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2033
Table 2. Key Players of PD-1 Inhibitors
Table 3. Key Players of PD-L1 Inhibitors
Table 4. Global Checkpoint Inhibitor Refractory Cancer Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2033
Table 5. Global Checkpoint Inhibitor Refractory Cancer Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 6. Global Checkpoint Inhibitor Refractory Cancer Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Checkpoint Inhibitor Refractory Cancer Market Share by Region (2018-2023)
Table 8. Global Checkpoint Inhibitor Refractory Cancer Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 9. Global Checkpoint Inhibitor Refractory Cancer Market Share by Region (2024-2033)
Table 10. Checkpoint Inhibitor Refractory Cancer Market Trends
Table 11. Checkpoint Inhibitor Refractory Cancer Market Drivers
Table 12. Checkpoint Inhibitor Refractory Cancer Market Challenges
Table 13. Checkpoint Inhibitor Refractory Cancer Market Restraints
Table 14. Global Checkpoint Inhibitor Refractory Cancer Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Checkpoint Inhibitor Refractory Cancer Revenue Share by Players (2018-2023)
Table 16. Global Top Checkpoint Inhibitor Refractory Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Checkpoint Inhibitor Refractory Cancer as of 2022)
Table 17. Global Checkpoint Inhibitor Refractory Cancer Industry Ranking 2021 VS 2022 VS 2023
Table 18. Global 5 Largest Players Market Share by Checkpoint Inhibitor Refractory Cancer Revenue (CR5 and HHI) & (2018-2023)
Table 19. Global Key Players of Checkpoint Inhibitor Refractory Cancer, Headquarters and Area Served
Table 20. Global Key Players of Checkpoint Inhibitor Refractory Cancer, Product and Application
Table 21. Global Key Players of Checkpoint Inhibitor Refractory Cancer, Product and Application
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Checkpoint Inhibitor Refractory Cancer Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Checkpoint Inhibitor Refractory Cancer Revenue Market Share by Type (2018-2023)
Table 25. Global Checkpoint Inhibitor Refractory Cancer Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 26. Global Checkpoint Inhibitor Refractory Cancer Revenue Market Share by Type (2024-2033)
Table 27. Global Checkpoint Inhibitor Refractory Cancer Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Checkpoint Inhibitor Refractory Cancer Revenue Share by Application (2018-2023)
Table 29. Global Checkpoint Inhibitor Refractory Cancer Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 30. Global Checkpoint Inhibitor Refractory Cancer Revenue Share by Application (2024-2033)
Table 31. North America Checkpoint Inhibitor Refractory Cancer Market Size by Type (2018-2023) & (US$ Million)
Table 32. North America Checkpoint Inhibitor Refractory Cancer Market Size by Type (2024-2033) & (US$ Million)
Table 33. North America Checkpoint Inhibitor Refractory Cancer Market Size by Application (2018-2023) & (US$ Million)
Table 34. North America Checkpoint Inhibitor Refractory Cancer Market Size by Application (2024-2033) & (US$ Million)
Table 35. North America Checkpoint Inhibitor Refractory Cancer Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 36. North America Checkpoint Inhibitor Refractory Cancer Market Size by Country (2018-2023) & (US$ Million)
Table 37. North America Checkpoint Inhibitor Refractory Cancer Market Size by Country (2024-2033) & (US$ Million)
Table 38. Europe Checkpoint Inhibitor Refractory Cancer Market Size by Type (2018-2023) & (US$ Million)
Table 39. Europe Checkpoint Inhibitor Refractory Cancer Market Size by Type (2024-2033) & (US$ Million)
Table 40. Europe Checkpoint Inhibitor Refractory Cancer Market Size by Application (2018-2023) & (US$ Million)
Table 41. Europe Checkpoint Inhibitor Refractory Cancer Market Size by Application (2024-2033) & (US$ Million)
Table 42. Europe Checkpoint Inhibitor Refractory Cancer Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 43. Europe Checkpoint Inhibitor Refractory Cancer Market Size by Country (2018-2023) & (US$ Million)
Table 44. Europe Checkpoint Inhibitor Refractory Cancer Market Size by Country (2024-2033) & (US$ Million)
Table 45. China Checkpoint Inhibitor Refractory Cancer Market Size by Type (2018-2023) & (US$ Million)
Table 46. China Checkpoint Inhibitor Refractory Cancer Market Size by Type (2024-2033) & (US$ Million)
Table 47. China Checkpoint Inhibitor Refractory Cancer Market Size by Application (2018-2023) & (US$ Million)
Table 48. China Checkpoint Inhibitor Refractory Cancer Market Size by Application (2024-2033) & (US$ Million)
Table 49. Asia Checkpoint Inhibitor Refractory Cancer Market Size by Type (2018-2023) & (US$ Million)
Table 50. Asia Checkpoint Inhibitor Refractory Cancer Market Size by Type (2024-2033) & (US$ Million)
Table 51. Asia Checkpoint Inhibitor Refractory Cancer Market Size by Application (2018-2023) & (US$ Million)
Table 52. Asia Checkpoint Inhibitor Refractory Cancer Market Size by Application (2024-2033) & (US$ Million)
Table 53. Asia Checkpoint Inhibitor Refractory Cancer Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 54. Asia Checkpoint Inhibitor Refractory Cancer Market Size by Region (2018-2023) & (US$ Million)
Table 55. Asia Checkpoint Inhibitor Refractory Cancer Market Size by Region (2024-2033) & (US$ Million)
Table 56. Middle East, Africa, and Latin America Checkpoint Inhibitor Refractory Cancer Market Size by Type (2018-2023) & (US$ Million)
Table 57. Middle East, Africa, and Latin America Checkpoint Inhibitor Refractory Cancer Market Size by Type (2024-2033) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Checkpoint Inhibitor Refractory Cancer Market Size by Application (2018-2023) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Checkpoint Inhibitor Refractory Cancer Market Size by Application (2024-2033) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Checkpoint Inhibitor Refractory Cancer Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 61. Middle East, Africa, and Latin America Checkpoint Inhibitor Refractory Cancer Market Size by Country (2018-2023) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Checkpoint Inhibitor Refractory Cancer Market Size by Country (2024-2033) & (US$ Million)
Table 63. Bristol-Myers Squibb Company Details
Table 64. Bristol-Myers Squibb Business Overview
Table 65. Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Product
Table 66. Bristol-Myers Squibb Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 67. Bristol-Myers Squibb Recent Developments
Table 68. AstraZeneca Company Details
Table 69. AstraZeneca Business Overview
Table 70. AstraZeneca Checkpoint Inhibitor Refractory Cancer Product
Table 71. AstraZeneca Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 72. AstraZeneca Recent Developments
Table 73. Merck Company Details
Table 74. Merck Business Overview
Table 75. Merck Checkpoint Inhibitor Refractory Cancer Product
Table 76. Merck Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 77. Merck Recent Developments
Table 78. Roche Company Details
Table 79. Roche Business Overview
Table 80. Roche Checkpoint Inhibitor Refractory Cancer Product
Table 81. Roche Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 82. Roche Recent Developments
Table 83. Regeneron Pharmaceuticals Company Details
Table 84. Regeneron Pharmaceuticals Business Overview
Table 85. Regeneron Pharmaceuticals Checkpoint Inhibitor Refractory Cancer Product
Table 86. Regeneron Pharmaceuticals Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 87. Regeneron Pharmaceuticals Recent Developments
Table 88. Bristol-Myers Squibb Company Details
Table 89. Bristol-Myers Squibb Business Overview
Table 90. Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Product
Table 91. Bristol-Myers Squibb Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 92. Bristol-Myers Squibb Recent Developments
Table 93. Janssen Research and Development Company Details
Table 94. Janssen Research and Development Business Overview
Table 95. Janssen Research and Development Checkpoint Inhibitor Refractory Cancer Product
Table 96. Janssen Research and Development Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 97. Janssen Research and Development Recent Developments
Table 98. 4D pharma Company Details
Table 99. 4D pharma Business Overview
Table 100. 4D pharma Checkpoint Inhibitor Refractory Cancer Product
Table 101. 4D pharma Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 102. 4D pharma Recent Developments
Table 103. 4SC AG Company Details
Table 104. 4SC AG Business Overview
Table 105. 4SC AG Checkpoint Inhibitor Refractory Cancer Product
Table 106. 4SC AG Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 107. 4SC AG Recent Developments
Table 108. OncoSec Medical Company Details
Table 109. OncoSec Medical Business Overview
Table 110. OncoSec Medical Checkpoint Inhibitor Refractory Cancer Product
Table 111. OncoSec Medical Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 112. OncoSec Medical Recent Developments
Table 113. Mirati Therapeutics Company Details
Table 114. Mirati Therapeutics Business Overview
Table 115. Mirati Therapeutics Checkpoint Inhibitor Refractory Cancer Product
Table 116. Mirati Therapeutics Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 117. Mirati Therapeutics Recent Developments
Table 118. Ascentage Pharma Group Company Details
Table 119. Ascentage Pharma Group Business Overview
Table 120. Ascentage Pharma Group Checkpoint Inhibitor Refractory Cancer Product
Table 121. Ascentage Pharma Group Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 122. Ascentage Pharma Group Recent Developments
Table 123. ENB Therapeutics Company Details
Table 124. ENB Therapeutics Business Overview
Table 125. ENB Therapeutics Checkpoint Inhibitor Refractory Cancer Product
Table 126. ENB Therapeutics Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 127. ENB Therapeutics Recent Developments
Table 128. Exicure Company Details
Table 129. Exicure Business Overview
Table 130. Exicure Checkpoint Inhibitor Refractory Cancer Product
Table 131. Exicure Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 132. Exicure Recent Developments
Table 133. Eisai Company Details
Table 134. Eisai Business Overview
Table 135. Eisai Checkpoint Inhibitor Refractory Cancer Product
Table 136. Eisai Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 137. Eisai Recent Developments
Table 138. Kartos Therapeutics Company Details
Table 139. Kartos Therapeutics Business Overview
Table 140. Kartos Therapeutics Checkpoint Inhibitor Refractory Cancer Product
Table 141. Kartos Therapeutics Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 142. Kartos Therapeutics Recent Developments
Table 143. Exelixis Company Details
Table 144. Exelixis Business Overview
Table 145. Exelixis Checkpoint Inhibitor Refractory Cancer Product
Table 146. Exelixis Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 147. Exelixis Recent Developments
Table 148. ImmunityBio Company Details
Table 149. ImmunityBio Business Overview
Table 150. ImmunityBio Checkpoint Inhibitor Refractory Cancer Product
Table 151. ImmunityBio Revenue in Checkpoint Inhibitor Refractory Cancer Business (2018-2023) & (US$ Million)
Table 152. ImmunityBio Recent Developments
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Checkpoint Inhibitor Refractory Cancer Market Size Growth Rate by Type, 2018 VS 2022 VS 2033 (US$ Million)
Figure 2. Global Checkpoint Inhibitor Refractory Cancer Market Share by Type: 2022 VS 2033
Figure 3. PD-1 Inhibitors Features
Figure 4. PD-L1 Inhibitors Features
Figure 5. Global Checkpoint Inhibitor Refractory Cancer Market Size Growth Rate by Application, 2018 VS 2022 VS 2033 (US$ Million)
Figure 6. Global Checkpoint Inhibitor Refractory Cancer Market Share by Application: 2022 VS 2033
Figure 7. Hodgkin Lymphoma Case Studies
Figure 8. Kidney Cancer Case Studies
Figure 9. Melanoma Case Studies
Figure 10. Non-Small Cell Lung Cancer Case Studies
Figure 11. Others Case Studies
Figure 12. Checkpoint Inhibitor Refractory Cancer Report Years Considered
Figure 13. Global Checkpoint Inhibitor Refractory Cancer Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 14. Global Checkpoint Inhibitor Refractory Cancer Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 15. Global Checkpoint Inhibitor Refractory Cancer Market Share by Region: 2022 VS 2033
Figure 16. Global Checkpoint Inhibitor Refractory Cancer Market Share by Players in 2022
Figure 17. Global Top Checkpoint Inhibitor Refractory Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Checkpoint Inhibitor Refractory Cancer as of 2022)
Figure 18. The Top 10 and 5 Players Market Share by Checkpoint Inhibitor Refractory Cancer Revenue in 2022
Figure 19. North America Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 20. North America Checkpoint Inhibitor Refractory Cancer Market Share by Type (2018-2033)
Figure 21. North America Checkpoint Inhibitor Refractory Cancer Market Share by Application (2018-2033)
Figure 22. North America Checkpoint Inhibitor Refractory Cancer Market Share by Country (2018-2033)
Figure 23. United States Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. Canada Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. Europe Checkpoint Inhibitor Refractory Cancer Market Size YoY (2018-2033) & (US$ Million)
Figure 26. Europe Checkpoint Inhibitor Refractory Cancer Market Share by Type (2018-2033)
Figure 27. Europe Checkpoint Inhibitor Refractory Cancer Market Share by Application (2018-2033)
Figure 28. Europe Checkpoint Inhibitor Refractory Cancer Market Share by Country (2018-2033)
Figure 29. Germany Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. France Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. U.K. Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Italy Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. Russia Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. Nordic Countries Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. China Checkpoint Inhibitor Refractory Cancer Market Size YoY (2018-2033) & (US$ Million)
Figure 36. China Checkpoint Inhibitor Refractory Cancer Market Share by Type (2018-2033)
Figure 37. China Checkpoint Inhibitor Refractory Cancer Market Share by Application (2018-2033)
Figure 38. Asia Checkpoint Inhibitor Refractory Cancer Market Size YoY (2018-2033) & (US$ Million)
Figure 39. Asia Checkpoint Inhibitor Refractory Cancer Market Share by Type (2018-2033)
Figure 40. Asia Checkpoint Inhibitor Refractory Cancer Market Share by Application (2018-2033)
Figure 41. Asia Checkpoint Inhibitor Refractory Cancer Market Share by Region (2018-2033)
Figure 42. Japan Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. South Korea Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. China Taiwan Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. Southeast Asia Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 46. India Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 47. Australia Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 48. Middle East, Africa, and Latin America Checkpoint Inhibitor Refractory Cancer Market Size YoY (2018-2033) & (US$ Million)
Figure 49. Middle East, Africa, and Latin America Checkpoint Inhibitor Refractory Cancer Market Share by Type (2018-2033)
Figure 50. Middle East, Africa, and Latin America Checkpoint Inhibitor Refractory Cancer Market Share by Application (2018-2033)
Figure 51. Middle East, Africa, and Latin America Checkpoint Inhibitor Refractory Cancer Market Share by Country (2018-2033)
Figure 52. Brazil Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 53. Mexico Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 54. Turkey Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 55. Saudi Arabia Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 56. Israel Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 57. GCC Countries Checkpoint Inhibitor Refractory Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 58. Bristol-Myers Squibb Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 59. AstraZeneca Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 60. Merck Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 61. Roche Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 62. Regeneron Pharmaceuticals Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 63. Bristol-Myers Squibb Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 64. Janssen Research and Development Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 65. 4D pharma Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 66. 4SC AG Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 67. OncoSec Medical Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 68. Mirati Therapeutics Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 69. Ascentage Pharma Group Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 70. ENB Therapeutics Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 71. Exicure Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 72. Eisai Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 73. Kartos Therapeutics Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 74. Exelixis Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 75. ImmunityBio Revenue Growth Rate in Checkpoint Inhibitor Refractory Cancer Business (2018-2023)
Figure 76. Bottom-up and Top-down Approaches for This Report
Figure 77. Data Triangulation
Figure 78. Key Executives Interviewed